458 results on '"Eitner, Frank"'
Search Results
2. Author Correction: Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits
3. Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits
4. Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease
5. Determinants of Successful Use of Sirolimus in Renal Transplant Patients
6. Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy
7. A flow cytometry approach reveals heterogeneity in conventional subsets of murine renal mononuclear phagocytes
8. Identification of platelet-derived growth factor C as a mediator of both renal fibrosis and hypertension
9. The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats
10. Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution
11. International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology
12. Role of Platelet-Derived Growth Factor-CC in Capillary Rarefaction in Renal Fibrosis
13. International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology
14. BAY-7081: A Potent, Selective, and Orally Bioavailable Cyanopyridone-Based PDE9A Inhibitor
15. Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)
16. Growth arrest–specific protein 1 is a novel endogenous inhibitor of glomerular cell activation and proliferation
17. Platelet-Derived Growth Factor (PDGF)-C Neutralization Reveals Differential Roles of PDGF Receptors in Liver and Kidney Fibrosis
18. Sirolimus in renal transplant recipients with malignancies in Germany
19. Induction of progressive glomerulonephritis by podocyte-specific overexpression of platelet-derived growth factor-D
20. TRPM2 Plays a Minor Role in AKI and Kidney Fibrosis
21. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
22. Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease
23. Differential activation of memory-relevant brain regions during a dialysis cycle
24. Models of IgA nephropathy
25. Analysis of Calcifications in Patients with Coral Reef Aorta
26. Analyse des calcifications chez les patients ayant une atteinte coralliforme de l’aorte
27. PDGF-C Mediates Glomerular Capillary Repair
28. Genetic regulation of serum IgA levels and susceptibility to common immune, infectious, kidney, and cardio-metabolic traits
29. YB-1 Acts as a Ligand for Notch-3 Receptors and Modulates Receptor Activation
30. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy
31. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study
32. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort
33. Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney
34. The PDGF family in renal fibrosis
35. Littoral Cell Angioma of the Spleen Mimicking Posttransplantation Lymphoma in a 63-Year-Old Renal Transplant Patient
36. Immune Modulating Therapy for IgA Nephropathy: Rationale and Evidence
37. Model-based correction of the influence of body position on continuous segmental and hand-to-foot bioimpedance measurements
38. HYPERTENSION: EXPERIMENTAL
39. Proteinuria and sirolimus after renal transplantation: a retrospective analysis from a large German multicenter database
40. Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)
41. Pharmacology of Free Fatty Acid Receptors and Their Allosteric Modulators
42. Pharmacological inhibition of Vanin-1 is not protective in models of acute and chronic kidney disease
43. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis
44. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage
45. Pilot study of non-contrast-enhanced MRI vs. ultrasound in renal transplant recipients with acquired cystic kidney disease: a prospective intra-individual comparison
46. Biological responses to PDGF-AA versus PDGF-CC in renal fibroblasts
47. Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms
48. Contributors
49. Acquired Cystic Kidney Disease and Malignant Neoplasms
50. Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.